UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 16, 2005

Access Ph	armaceuticals, In	nc.	
(Exact name of re	gistrant as speci	fied in its char	rter)
Delaware			517
(State of Incorporation)			(I.R.S. Employer
2600 Stemmons Free	way, Suite 176,	Dallas, Texas	75207
(Address of principa	al executive offi	ces) ((Zip Code)
Registrant's telephone	number, includir	ng area code:	(214) 905-5100
Check the appropriate bo the filing obligation of th (see General Instruction	e registrant und		
[] Written communicati (17 CFR 230.425)	ons pursuant to	Rule 425 und	er the Securities Act
[] Soliciting material pt (17 CFR 240.14a-12)	rsuant to Rule 1	4a-12 under t	he Exchange Act
[] Pre-commencement of Exchange Act (17 CFR 2		pursuant to R	ule 14d-2(b) under the
[] Pre-commencement of Exchange Act (17 CFR 2		pursuant to R	ule 13e-4(c) under the
Item 7.01 Regulation FD	Disclosure.		
On March 16, 2005, the	Registrant filed :	a Form 12h-2	5 with the Securities

On March 16, 2005, the Registrant filed a Form 12b-25 with the Securities and Exchange Commission pursuant to which it reported that its Annual Report on Form 10-K for the fiscal year ended December 31, 2004 could not be filed within the prescribed time period without unreasonable effort or expense and that such Annual Report on Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date.

The registrant has experienced delays in completing management's assessment of the effectiveness of the registrant's internal controls over financial reporting and the completion of the audits by our audit firm of the registrant's financial statements and internal controls over financial reporting for the year ended December 31, 2004 as required under Section 404 of the Sarbanes Oxley Act of 2002. As a result of the complex nature of the new requirements under Section 404, the registrant is unable to complete and file the 2004 Annual Report by the prescribed filing date without

unreasonable effort and expense. The registrant continues to dedicate significant resources to the audit of the financial statements, internal control testing and reporting, and the 2004 Annual Report. The registrant anticipates filing the 2004 Annual Report on or before the extended deadline of March 31, 2005.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Access Pharmaceuticals, Inc. (Registrant)

By: /s/ Stephen B. Thompson

Stephen B. Thompson Vice President and Chief Financial Officer

Dated March 16, 2005

3